Conatus Pharmaceuticals Priced, Nasdaq: CNAT
Biotech in Phase 2 trials developing treatments for chronic liver disease.
Industry: Health Care
First Day Return: -13.6%
CNAT
Biotech in Phase 2 trials developing treatments for chronic liver disease.
| IPO Data | |
|---|---|
| IPO Date | 07/24/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $66 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2005 |
| Employees at IPO | 15 |
| Website www.conatuspharma.com | |
IPO News for Conatus Pharmaceuticals
Conatus Pharmaceuticals (CNAT) Performance
